Takeaway
In patients with PRRT2-associated infantile epilepsy, sodium channel blockers, such as oxcarbazepine and carbamazepine, can reduce seizure frequency but levetiracetam cannot.
Why this matters
Pathogenic variants in PRRT2 have been identified as the main cause of self-limiting sporadic and familial infantile epilepsy, but data on treatment response to different antiseizure medications (ASMs) is lacking in these patients, which extends the time to optimal treatment.
Assessing the treatment responses to currently available ASMs can guide treatment choices for patients with PRRT2-associated infantile epilepsy to achieve improved outcomes.